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Sodium transport in red blood cells from dialyzed uremic patients.
Studies on red blood cell (RBC) sodium (Na) transport in chronic renal
failure have described abnormalities in the ouabain—sensitive Na, K
pump. We now report Na transport in RBC using cation flux method-
ology, measuring both the ouabain—sensitive Na, K pump and the
ouabajn—insensitive Na, K cotransport (CoT) and Na, lithium (Li)
countertransport (CTT) in 28 subjects on hemodialysis, eight subjects
on chronic ambulatory peritoneal dialysis (CAPD) and 29 control
subjects. Intracellular cation content and passive permeability of Na
were also examined. Mean Na efflux through the ouabain—sensitive Na,
K pump was not reduced in dialysis patients when compared to normal
subjects, whether measured in fresh cells (1.41 0.05 vs. 1.30 0.03
mmole/liter RBCIhr; P < 0.05) or in Na-loaded cells (7.10 0.24 vs.
6.90 0.22; NS). There was, however, a marked and uniform suppres-
sion of the CoT pathway in Na-loaded cells from dialysis patients
versus controls (0.14 0.02 vs. 0.41 0.05 mmole/liter RBCIhr; P <
0.001). Mean CTT activity, as measured by Li efflux, was not different
between dialysis and normal subjects. Uremic and normal RBC had
similar intracellular Na or K content as well as passive permeability for
either ion. This indicates that intracellular cationic homeostasis is
maintained, perhaps secondary to balanced changes in cationic flux
activity through these transport pathways.
Considerable previous interest has been focused on the effect
of renal failure on sodium (Na) transport [1—5]. Although the red
blood cell (RBC) has several well characterized Na transport
mechanisms [6—9], the effect of renal failure on all these
pathways has not been extensively described. Most studies
have focused on the ouabain—sensitive Na, K pump identified
by the membrane Na, K-stimulated adenosine triphosphatase
(Na, K-ATPase) enzyme system or as pump—mediated Na and
K fluxes, with the general conclusion that uremia suppresses
the activity of this pathway. The RBC has other characterized
Na transport pathways, including the Na, K cotransport (CoT)
and the Na, Na or Na, lithium (Li) countertransport (CTT)
systems. These pathways are ouabain—insensitive with the CoT
system being inhibited by furosemide and the CTT system by
phloretin. We studied Na transport by cation flux methodology
through these three transport pathways in RBCs from uremic
patients treated by chronic dialysis. Mean Na efflux through the
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ouabain—sensitive, Na, K pump, rather than inhibited, was
normal to slightly increased in some individuals. Mean Na
efflux through the furosemide—sensitive, Na, K cotransport
pathway was markedly depressed in all patients. The Na, Li
countertransport pathway was not different between dialysis
patients and normal subjects. These results have been reported
in preliminary forms [10, 11] and have been confirmed in
general by Quarello and associates [12].
Methods
Patients
Thirty—five male patients and one female patient with
end—stage renal disease (ESRD) and receiving chronic mainte-
nance dialysis were studied. Pertinent clinical and pre-
dialysis biochemical findings are depicted in Table I. The age
range in this Caucasian patient population was 28 to 86 years
(mean 59.6 10.4). The etiologies of ESRD and the number of
patients, in parentheses, were as follows: essential hyperten-
sion (seven), polycystic kidney disease (nine), chronic glomer-
ulonephritis (eight), chronic interstitial nephritis (six), diabetic
nephropathy (four), renal adenocarcinoma (one) and Alport's
syndrome (one). Twenty—eight patients were maintained on
intermittent hemodialysis while the other eight patients re-
ceived chronic ambulatory peritoneal dialysis (CAPD).
Hemodialysis patients received three, four-hr dialysis weekly.
All patients receiving acetate dialysis were dialyzed against a
bath with the following composition (mEq/liter): sodium 135;
calcium 3.5; potassium 2; magnesium 1.5; chloride 105; acetate
31 and dextrose 2 g/liter. Patients who received bicarbonate
dialysis were dialyzed against a bath with the following com-
position (mEq/liter): sodium 135; calcium 3.5; potassium 2;
magnesium 1.5; chloride 105; bicarbonate 35 and dextrose 2
g/liter. CAPD patients were treated with three to four two—liter
exchanges daily using a solution composed of (mEq/liter):
sodium 132; calcium 3.5; magnesium 1.5; chloride 102; lactate
35; and variable dextrose concentrations. All hemodialysis
patients were normotensive or mildly hypertensive with predi-
alysis mean systolic and diastolic blood pressure of 148 6 and
82 3 mm Hg, respectively. Thirteen of the 28 patients were
receiving antihypertensive medications. All the CAPD patients
were normotensive without medications at the time of the
study. The normal population studied consisted of 11 male and
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18 female Caucasian subjects with an age range from 22 to 53
years (mean 41.7 7.9). All subjects were normotensive and
had no significant medical problems. Eight normal offsprings of
five dialysis patients were also studied.
Methods
Cellpreparation. Fresh venous blood was collected between
0800 to 1000 hr in both control subjects and dialysis patients. In
hemodialysis patients, post-dialysis blood samples were also
obtained immediately after completion of dialysis. Blood was
collected into heparinized tubes, centrifuged at 1,750 x g for
ten minutes, and the plasma and buffy coat were removed by
aspiration. RBCs were washed twice at 4°C with approximately
10 volumes of cold 110 m magnesium chloride (MgCI2) and
recentrifuged. RBCs were Na-loaded and K-depleted by the
2,5-p-chloro-mercuribenzene sulfonate (PCMBS) method [8—9].
Four muter of packed RBCs were suspended in a loading
solution containing the following (mM): sodium chloride 55,
potassium chloride 3, choline chloride 150, sodium phosphate
2.5, magnesium chloride I, EGTA 1 and PCMBS 0.02. After 20
hr incubation at 4°C in a slow speed shaker, the solution was
again centrifuged, the supernatant removed, and the cells were
resuspended for one hour at 37°C in a recovery solution
containing the following (mM): sodium chloride 150, magnesium
chloride I, sodium phosphate 5.4, cysteine 4, adenine 2, inosine
3, EGTA 1, glucose 10 and Tris buffer to adjust pH to 7.2. The
suspension was then recentrifuged, the supernatant was re-
moved and the cells were washed five times in cold, 110 mM,
MgCI2 solution. After the final washing, the cells were either
resuspended in the same solution, giving a final concentration of
approximately 50% for determination of hematocrit and mea-
surement of intracellular Na and K, or used for flux studies
described below.
Intracellular Na and K. intracellular Na and K concentra-
tions were measured in washed cells at 50% cell suspension.
Aliquots of 0.2 mliter of this suspension were mixed with 9.8
muter of 0.02% Acationex detergent (American Scientific Prod-
ucts, McGraw Park, Illinois, USA) to produce complete lysis of
erythrocytes. The suspension was then centrifuged and the Na
and K concentrations in the supernatant measured using an
atomic absorption spectrophotometer (Model 5000, Perkin—
Elmer, Norwalk, Connecticut, USA). Results are expressed in
mmole/liter RBC.
Na, K pump and Na, K cotransport. These monovalent
cation flux assays were a modification of the method of Cusi and
Garay [9]. Na fluxes through these pathways were estimated by
measuring the rate of Na efflux from Na-loaded cells into
Na-free, Mg-sucrose medium with the following composition in
m concentration: MgCI, 75, sucrose 85, and Tris-MOPS 10 at
pH 7.2. Washed packed cells (1 muter) were incubated in a total
of 2 muter suspension at 37°C with continuous mechanical
agitation in each of three tubes: I) Mg-sucrose control contain-
ing 5 mM KCI; 2) Mg-sucrose plus ouabain (0.1 mM); 3)
Mg-sucrose plus ouabain plus furosemide (1 mM), The reaction
was stopped by sudden cooling to 0°C for two mm, followed by
centrifugation and the measurement of Na concentration in the
supernatant. The Na elilux rate was calculated in mmole/liter
RBC/hr by dividing the rate of Na extrusion by the final
hematocrit in the Mg-sucrose suspension. The difference in Na
fluxes into Mg-sucrose medium and Mg-sucrose plus ouabain
medium after 60 mm incubation at 37°C defined Na, K
pump—mediated Na efflux. The activity of the ouabain—insensi-
tive, furosemide—sensitive CoT was measured by the difference
in Na efflux into Mg-sucrose (K-free) plus ouabain medium, and
Na efflux into Mg-sucrose (K-free), plus ouabain, plus furose-
mide medium after 180 mm incubation at 37°C. In separate
studies, fresh RBCs (without Na-loading) were taken for pump
and CoT flux studies as described above after a single MgCl2
(110 mM) wash.
Na, Li countertransport. The assay is identical to that
originally described by Canessa et al [131. Freshly isolated
RBCs were washed four times at 4°C using an isosmotic
washing solution containing (mM): MgCI2 75, sucrose 85, glu-
cose 10, and Tris-MOPS 20. Packed RBCs (4 mliter) were
incubated for three hr at 37°C in 25 mliter of 150 mrvt LiCI, 10
mM glucose and 10 mrt Tris-MOPS. Cells were then washed
five times and the final cell suspension made up to 50%
hematocrit. Aliquots were taken for hematocrit, intracellular Li
and cell water content. Li efflux was measured by incubating
Li-loaded cells (I mliter) in 10 mliter of Na-free (Mg-sucrose) or
Na-rich (ISO ms'i NaCI) media in the presence of 0.1 mvi
ouabain. Samples were taken at 15 and 30 mm of incubation.
Cells were separated by centrifugation and the supernatant
taken for analysis of Li using an atomic absorption spectropho-
tometer and read against 5 to 150 mrvi LiCI standards. The
difference in Li efflux into Na-free and Na-rich media repre-
sents the activity of ouabain—insensitive, Na, Li counter-
transport.
Statistical analysis. Cation efflux rates for the three pathways
are expressed in mmole/liter RBC/hr. All data are reported as
mean SEM. Statistical significance is evaluated using Stu-
dent's t-test.
Results
In all the following measurements, with the exception of Na,
Li countertransport, no difference was observed in Na, K pump
or cotransport, either between the hemodialysis and CAPD
patients or between pre- and post-dialysis studies in
hemodialysis patients (Table 2). Therefore, except for Na, Li
countertransport, each measurement from the three groups of
patients, that is, pre-dialysis, post-dialysis, and CAPD samples
were combined and referred to as a single group of dialysis
patients. Likewise, no difference in RBC transport activity was
Table 1. Selected laboratory and clinical parameters in dialysis
patients
Sodium transport in uremic erythrocytes 1199
Table 2. Intracellular Na concentrations and Na efilux rates through
pump and CoT pathways in hemodialysis and chronic ambulatory












Pre-hemodialysisN = 8 7.83 0.85 6.73 0.62 0.122 0.04
Post-hemodialysisN = 8 7.12 0.64 6.87 0.62 0.176 0.11









Table 3. Red blood cell Na and K concentrations (mM/liter cells)
measured before (pre) and after (post) Na-loading by the PCMBS




Pre 8.8 0.5 7.5 0.5
Post 20.2 1.1 27.8 0.9*
K
Pre 81.1 11.6 85.9 3.0











Fig. 1. Mean and individual values for ouabain—sensitive sodium efflux
in sodium—loaded RBC and in fresh RBC from normal controls (N) and

































* P < 0.01 compared to controls.
noted between normotensive and hypertensive patients so their
results were combined.
Intracellular concentration of Na and K
Table 3 shows that mean Na and K concentrations in RBCs
from dialysis patients were similar to normal subjects. The
intracellular Na and K concentrations following incubation in
the Na-loading solution using PCMBS are also tabulated. So-
dium concentration rose in both normal and uremic cells,
however, the accumulation rate was higher in RBCs from
dialysis patients. Cellular K decreased with Na-loading but the
final concentration was not different between normal and ure-
mic cells.
Na, Kpump
Figure 1 shows that the mean values for ouabain—sensitive Na
efflux rates in sodium—loaded cells were not significantly dif-
ferent in dialysis patients compared to controls. However,
some dialysis patients demonstrated quite high individual val-
ues for Na efflux. Because Na-loading resulted in higher intra-
cellular Na in uremic cells (Table 3), it was possible that this
elevation in Na concentration could artifactually increase Na,
K pump activity in uremic cells. In order to examine this
possibility, ouabain—sensitive Na efflux rate was measured in
fresh cells in which intracellular Na concentration was not
different between normal and dialysis patients. Although the
magnitude of the ouabain—sensitive Na efflux rate in fresh cells
was lower, a higher rate of mean Na efflux rate was seen in the
dialysis population (Fig. 1).
Na, K cotransporl
Furosemide—sensitive Na efflux or Na, K CoT measured in
both Na-loaded and fresh cells was significantly reduced in
dialysis patients (Fig. 2). In several patients there was a virtual
absence of RBC cotransport activity. In contrast, RBCs from
N D N D
IN = 2911N = 361 IN = 17) (N = 161
Fig. 2. Mean and individual values for ouabain—insensitive,
furosemide—sensitive sodium efflux (cotransport) in sodium—loaded
RBC and fresh RBC from normal controls (N), and dialysis patients
(D).
eight offspring in five families demonstrated higher cotransport
activities compared to his or her parent. The mean values of the
offspring (0.39 0.06) and patients (0.07 0.03, RBC/hr) were
statistically different (P < 0.01). There was no difference in Na,
K CoT between hypertensive and normotensive dialysis pa-
tients.
Na, Li countertransport
Figure 3 shows that there was no significant difference in
predialysis mean Na, Li countertransport between dialysis and
normal subjects. Six dialysis patients did have countertransport
values greater than 0.5 mmole/liter RBC/hr, values considered
elevated for our laboratory. In 14 patients on maintenance
hemodialysis therapy, the mean activities of Na, Li
countertransport were not different whether studied pre- or
immediately post-dialysis (0.25 0.09 vs. 0.29 0.05). How-
ever, in patients treated with acetate dialysate there was a
significant increase in CTT activity post-dialysis (0.27 0.08
vs. 0.35 0.07; P <0.05). On the other hand, patients treated
with bicarbonate dialysate CTT was reduced following dialysis
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(0.31 0.08 vs. 0.23 0.09), although the difference did not
achieve statistical significance.
Passive permeability of Na and K
Cation permeability was measured as the efflux rate constant
for Na and K from Na-loaded cells in the presence of ouabain
and furosemide. The efflux rate in mmole/liter RBC/hr was
factored by the initial intracellular cation concentration and
expressed as a rate constant. Passive permeability was not
different between dialysis patients and normal subjects, either
for Na: 0.027 0.005 vs. 0.029 0.009 per hr; or for K: 0.008
0.001 vs. 0.010 0.003 per hr.
Discussion
Welt et al [1, 14] first reported that RBCs in some uremic
subjects have increased intracellular Na concentration associ-
ated with decreased Na efflux rate constants and reduced
membrane Na, K-ATPase enzyme activity. Subsequent studies
confirmed a reduced Na transport activity in RBCs [2, 15—181
and leukocytes [19] in chronic renal failure. Our studies of RBC
Na, K pump in dialyzed uremic patients shows a normal to
slightly increased rate of ouabain—sensitive Na efflux from
Na-loaded or unaltered, fresh RBCs. Differences in the choice
of Na transport assay to measure pump activity as well as
patient selection may explain the differences in our results
compared to previous studies. Most earlier studies examined
non-dialyzed renal failure patients, and the subset who dis-
played abnormal RBC Na transport were often those with the
severest renal failure who were usually seriously ill patients.
Similar abnormalities in RBC Na transport have been described
in non-azotemic, critically ill patients [141.
Measurable components of the RBC Na, K pump include
ouabain—binding, Na, K-ATPase activity and ouabain—sensitive
cation transport. Since the purpose of the present study was to
examine Na fluxes through the three major RBC Na transport
pathways in uremia, we have examined ouabain—sensitive Na
efilux as an index of pump activity. Thus, our findings of normal
to increased Na efflux in the dialysis patients does not exclude
abnormalities in uremia in other components of the Na, K
pump, including membrane ATPase activity or ouabain binding
capacity. Recent studies have examined RBC Na, K pump in
chronically hemodialyzed uremic patients, providing a more
comparable study population to our patients. lzumo et al [201
found normal RBC ouabain—binding capacity in chronic dialysis
patients, suggesting that this component of the Na, K pump is
intact in uremia. However, examination of ouabain—sensitive K
influx in RBCs from their patients using 86Rb as a K substitute,
showed reduced rates of influx that corrected with dialysis.
Cheng, Kahn and Kaji [21] found somewhat different results in
RBC pump function in their dialysis patients. Their patients
segregated into two populations based on serum creatinine
levels. The group with higher serum creatinine (17.0 4.1
mg/dliter) had elevated intracellular Na and had reduced RBC
ouabain—binding, whereas the group with lower creatinine (13.4
5.1 mgldliter) had normal internal Na and ouabain—binding.
These authors suggested that RBC Na may reflect adequacy of
dialysis. Our patients (mean serum creatinine 11.9 0.6
mg/dliter) and those of Izumo et al [20] would correspond to the
more adequately dialyzed patient population of Cheng et al with
normal intracellular Na and ouabain—binding. Thus, the profile
of RBC pump activity in uremic patients would be normal
intracellular Na, normal Na efilux, diminished K influx and
normal number of pump units in adequately dialyzed patients;
elevated internal Na, reduced number of pump units and
diminished K influx in inadequately dialyzed patients.
In addition to the ouabain—sensitive, Na, K pump, the RBC
has ouabain—insensitive Na transport pathways, including the
Na, K cotransport system and the Na, Na or Na, Li
countertransport system, The finding that Na efflux through the
CoT pathway is uniformly low to absent in RBCs from our
patients reflects a new abnormality in regulation of cellular
cation homeostasis in uremia. Reduction [9, 22—25] as well as
elevation of RBC Na, K CoT levels has been described in
essential hypertension [26]. Family analysis of normotensive
offspring of essential hypertensive subjects showed that RBC
CoT function may be genetically regulated [24]. The finding of
uniformly low to absent Na, K CoT in our patients suggests that
environmental factors, such as uremia, can also modulate CoT
activity. The normal Na, K CoT activity in the offspring of five
patients and the fact that there was no difference in CoT
between normotensive and hypertensive uremic patients lend
further support to the contention that non-genetic factors can
affect CoT function in the RBC. It is interesting to note that
careful reading of Table 1 of the study by Garay and associates
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Fig. 3. Mean and individual values for sodium, lithium countertransport
in RBC from normal controls (N) and dialysis patients (D).
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The cause for the uremia—associated reduction in CoT is not
clear. It has been suggested by Duhm and Gobel [27] that the
furosemide-sensitive Na, K transport system participates in
plasma K homeostasis. They demonstrated an inverse correla-
tion between extracellular K concentration [K] and the activity
of this cotransport system in extruding K from RBC. At [K] in
the hypokalemic range, K effiux was relatively high, but with
step—wise increases in external [K], there was a progressive
reduction in CoT-mediated K efflux, which became completely
suppressed at [K] of 10 mit. The observations of Korif and
associates [28] that RBCs from hypokalemic patients with
Bartter's syndrome exhibited increased Na, K CoT activity,
and that this abnormality was corrected with restoration of
eukalemia, are consistent with the findings of Duhm and Gobel
[27]. Since the predialysis [K] in our patients was 5.0 0.1 mM,
it is possible that some of the reduction in Na, K CoT activity
may be a direct result of this mild hyperkalemia. However, we
believe this to be an unlikely explanation because suppression
of cotransport was observed also in patients who were not
hyperkalemic. Moreover, CoT activity was unaltered by dialy-
sis which consistently reduced serum [K]. The physiologic
significance of this marked suppression in CoT activity is also
uncertain and can only be speculated at this time. It is interest-
ing to note that the same furosemide—inhibited CoT mechanism
probably also operates in the diluting segment of the nephron
[29] where furosemide inhibition of Na transport is known to
cause potent natriuresis. Our study, therefore, raises the ques-
tions whether a similar reduction in CoT function also occurs in
the diluting segment of uremic nephrons, and if so, whether
such reductions could account for the natriuresis observed in
chronic renal insufficiency.
Red blood cells loaded with Li activate a one—to--one ex-
change of intracellular Li for extracellular Na through the
phloretin—sensitive Na-Na countertransport system [6, 16].
Woods, Parker and Watson [30], based on a study of 12 Black
patients with end—stage renal failure associated with essential
hypertension, and three normal Caucasian subjects, concluded
that in both normal and uremic patients, the activity of the RBC
countertransport system is sustained by the presence of a
dialyzable plasma factor. In renal failure patients the removal of
this factor by dialysis or ultrafiltration led to depression of
Na-Li exchange. RBCs from normal subjects incubated in
normal plasma or pre-dialysis plasma from uremic patients
maintained their countertransport activity, but the same cells
incubated in post-dialysis plasma or in protein—free saline
medium demonstrated marked suppression of countertransport
activity. We found that countertransport activity in uremic
patients, irrespective of etiology, is not different from normal
control subjects. We also found that the mean value from
predialysis samples was not different from post-dialysis sam-
ples.
In conclusion, the suppression of ouabain—sensitive Na, K
pump activity previously described in uremic subjects was not
found in our dialysis patients as quantitated by cation flux
methodology. The demonstration of a normal Na effiux through
this pathway suggests that the capacity of the Na, K pump is
intact in uremic subjects on chronic maintenance dialysis. The
uniformly low CoT in our patients remains unexplained but the
normal CoT in their first—degree relatives suggests that environ-
mental factors in addition to genetic determinants can modulate
the activity of this transport pathway.
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